ASH 2023 | Thromboembolic event rates in patients with PV: a real-world analysis
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, comments on a real-world analysis investigating the rate of thromboembolic events (TEs) in patients with polycythemia vera (PV). This analysis included over 20,000 US patients and took into account TEs prior to and following PV diagnosis. Dr Kuykendall emphasizes that, although patients with prior history of TE were at greatest risk of another event, TE risk is high in all patients, even those considered ‘low-risk’. Clinicians must continue to focus on decreasing TE risk as the primary treatment goal in PV. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Celgene/BMS, Cogent, Incyte, Abbvie, Imago, Novartis, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm
Research Funding: MorphoSys, BMS, Protagonist Therapeutics, Janssen
Advisory Board: Dark Blue Therapeutics
